News

PDX Enterprise Pharmacy System integrates Armada Health Care’s ApproveRx

BY Michael Johnsen

FORT WORTH, Texas — Armada Health Care and PDX on Friday announced that Armada’s prior authorization solution, known as ApproveRx, will be integrated with the PDX Enterprise Pharmacy System, PDX Classic and Community Pharmacy system, PDX’s newest system. ApproveRx is an online platform that streamlines the prior authorization process for all pharmacies and prescribers, allowing healthcare professionals to quickly locate and submit prior authorization forms for virtually all drugs and insurance plans. 
 
The integration will produce a continuous pharmacy dispensing workflow and optimal efficiencies. Using the integrated functionality, pharmacies can automate the selection and completion of the appropriate prior authorization form, saving time searching for the appropriate and most current insurance form. The pharmacy can then electronically send the prior authorization request to any prescriber or health plan eliminating the need for paper faxes. The system allows for monitoring the status of all prior authorization submissions.
 
The use of ApproveRx provides PDX pharmacies with a method for initiating and managing prior authorizations within the current workflow. “It is important to PDX that pharmacies have technologies they need to work smarter and faster. By integrating Armada Health Care’s prior authorization program, PDX pharmacies will have access to a utility that will help streamline the prior authorization process,” said Jeff Farris, CEO of PDX. “We remain focused on delivering solutions and services our pharmacy partners require to remain efficient, such as those offered by Armada.”
 
“Industry reports predict a 63% increase in specialty-drug spend between 2014 and 2016, so it’s becoming progressively more important for pharmacy systems to be able to fill and get reimbursed for high-cost medications that require prior authorization approvals,” added Lawrence Irene, CEO of Armada Health Care. “Armada’s partnership with PDX effectively helps fill this need in the marketplace, and helps PDX capture the specialty spend.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

AccentHealth enters into strategic relationship with American Cancer Society

BY Michael Johnsen

 

NEW YORK – AccentHealth on Thursday announced it has entered into a strategic relationship with the American Cancer Society. The announcement follows the recent launch of the AccentHealth Oncology Network, which features CNN-produced television programming for cancer patients in the waiting room, as well as printed "health panels" with oncology-specific educational information.
 
The companies plan to jointly develop oncology-specific content that will be integrated into the AccentHealth Oncology Network patient education products.
 
"AccentHealth recognizes that there is an increasing need for patient education around disease management and supportive care for cancer patients," said John Curbishley, EVP, business and product development for AccentHealth. "The growing financial and time pressures on oncologists make it more challenging for them to deliver critical information to their patients during diagnosis and treatment. Together, AccentHealth and the American Cancer Society can help by delivering trusted content that will educate and support cancer patients during this difficult time." 
 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA approves diabetes drug Afrezza

BY David Salazar

WASHINGTON — Afrezza, an inhaled insulin powder meant to treat diabetes patients, was approved Friday by the Food and Drug Administration.

 

The powder — manufactured by MannKind Corp. — is an inhalable dose of insulin that can be taken before meals to control blood sugar for patients with Type 1 and Type 2 diabetes. The drug is not meant to replace long-acting insulin in patients with Type 1 diabetes.

 

Along with approval, the FDA is requiring more clinical trials to test whether Afrezza is safe and effective for pediatric patients. Additionally, the approval comes with a plan to let doctors and pharmacists know that the drug poses a risk of acute bronchospasm when used by patients with asthma or Chronic Obstructive Pulmonary Disease.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?